Carriers of APOA5, GPIHBP1, or LMF1 variants exhibited intermediate TG levels (1800–2500 mg/dL) and substantial pancreatitis risk, whereas APOB and APOC3 variant carriers had milder TG elevations (500–1500 mg/dL) but were more frequently associated with hepatic steatosis and metabolic comorbidities. This evidence concerns the gene GPIHBP1 and fatty liver disease.